CD19 and neoplasm: CD19-directed CAR-T therapy achieved meaningful success in refractory/relapsed (R/R) chronic lymphocytic leukemia (CLL) patients, and the results warrant subsequent clinical trials that explore CAR-T therapy targeting different tumor antigens in various types of hematological malignancies.